Please ensure Javascript is enabled for purposes of website accessibility

Zydus launches first generic of Nelarabine Injection! Learn more.

Access our product Medication Guides

Who is Zydus

Company Milestones

Zydus currently offers over 80 FDA-approved generic products across a wide variety of therapeutic categories in the US. To learn more about our history, select one of the time frames below.

The Beginnings 2001 - 2006 2007 - 2012 2013 - 2018 2019 & Beyond
Pre 2000

1950s – 1960s – Cadila made a mark with innovative medicines such as Livirubra, the first of its kind in India to treat pernicious anemia

Pre 2000

1952 – Cadila Laboratories Ltd. established by Mr. Ramanbhai B. Patel

Pre 2000

1970s – 1980s – Cadila became a benchmark for Quality and Excellence

Pre 2000

1995-1996 – Acquired Indo Pharma Pharmaceutical Works Ltd – the group’s first acquisition

Pre 2000

1995-1996 – Launched 23 new products in 1995, with first-in-India like Falcigo

Pre 2000

1995-1996 – Zydus’s journey began with Rs 250 crs.

Pre 2000

1997-1998 – Entered into JV with BYK Gulden, a German pharma major to set up a 50:50 JV

Pre 2000

1999-2000 – Entered into capital markets through Initial Public Offering (IPO)

Pre 2000

1999-2000 – Entered into JV with Sarabhai for consolidating its position in Animal Healthcare

Pre 2000

2000-2001 – Acquired Recon Healthcare, which boosted Zydus’s strengths in southern markets

Pre 2000

2000-2001 – Zydus Research Centre set up at Moraiya

Pre 2000

2000-2002 – Acquired German Remedies – the largest M&A in the Indian pharmaceutical sector at the time

01-06

2001-2002 – Acquired Aten and attained the top spot in the cardiovascular segment in India

01-06

2001-2002 – Acquired USFDA approved API plant,
Banyan Chemicals

01-06

2002-2003 – Zydus Pharmaceuticals (USA) Inc. incorporated

01-06

2003-2004 – Acquired Alpharma France (renamed Zydus France) – Zydus’s first international acquisition

01-06

2004-2005 – Filed first IND in India for ZYH11

01-06

2005-2006 – Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd

01-06

2006-2007 – Acquired Liva Healthcare and entered the dermatology market in India

01-06

2006-2007 – Acquired Nippon Universal and entered the Japanese market

07-12

2007-2008 – Entered into branded generic market of Brazil with the acquisition of Quimica e Farmaceutica Nikkho do Brasil Ltda

07-12

2008-2009 – Acquired Laboratorios Combix in Spain, Simayla Pharma in South America, and Etna Biotech in Italy

07-12

2009-2010 – Launched first formulation using nano-technology platform in India – Oxalgin Nanogel

07-12

2010-2011 – Achieved $1 billion in sales

07-12

2010-2011 – Entered into a 50:50 JV with Bayer to set up a new marketing company

07-12

2010-2011 – Entered into strategic agreement with Abbott for commercializing branded generics in emerging markets

07-12

2010-2011 – Launched Vaxiflu – S, India’s first H1N1 vaccine

07-12

2011-2012 – Acquired 100% stake in Biochem, one of the top 40 pharma companies in India

07-12

2011-2012 – Acquired Bremer Pharma GmbH to gain a global footprint in the animal healthcare business

07-12

2011-2012 – Acquired the assets of US-based Nesher Pharmaceuticals Inc.

07-12

2011-2012 – Received USFDA approval of Baddi manufacturing plant

07-12

2012-2013 – Over 114 new products launched during the year, 31 of which were first in India launches

13-18

2013 – Received USFDA approval for initiating Phase I clinical trials of ZYDPLA1, a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes

13-18

2014 – Zydus launched world’s first biosimilar of adalimumab

13-18

2015 – Zydus began Phase III study of saroglitazar in NASH

13-18

2016 – Zydus acquired Zoetis, a global animal health company

13-18

2016 – Zydus and Takeda entered into partnership to address emerging infection diseases

13-18

2016 – Zydus began supplying product in the US market from its SEZ facility

13-18

2016 – Zydus received approval from the USFDA to initiate Phase II clinical trials of saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in the US

13-18

2016 – Zydus’s Nesher Pharmaceuticals received its first ANDA approval, dextroamphetamine tablets

13-18

2017 – Zydus Cadila acquired Sentynl Therapeutics Inc., US-based specialty company

13-18

2017 – Zydus launched India’s first Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4

13-18

2017 – Zydus received regulatory approval of LipaglynTM in Mexico

13-18

2017 – Zydus received USFDA approval to initiate Phase II clinical studies of saroglitazar in patients with Primary Biliary Cholangitis (PBC)

13-18

2017 – Zydus started Phase II trial of ZYAN1 for treating anemia in patients with CKD

13-18

2018 – Cadila Healthcare acquired 51% stake in Windlas Healthcare

13-18

2018 – Zydus partnered with Medicure to launch its NDA product, ZYPITAMAG

2019+

2019 – Zydus received USFDA approval for its first transdermal product, rivastigmine transdermal system.

2019+

2019 – Zydus Wellness Ltd. completed the acquisition of Heinz India Private Limited.

2019+

2020 – Zydus began supplying product in the US market from its Liva facility.

2019+

2020 – Cadila Healthcare Ltd. received USFDA approval to initiate clinical trials of desidustat in chemotherapy induced anemia (CIA).

2019+

2020 – Zydus granted fast track designation by USFDA for Saroglitazar Mg in the treatment of patients with Primary Biliary Cholangitis (PBC).

2019+

2021 – Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar Mg in the treatment of patients with Primary Biliary Cholangitis (PBC).

2019+

2021 – Zydus Cadila’s ZyCoV-D vaccine, the first plasmid DNA vaccine to be approved for human use in the world, was granted Emergency Use Authorization in India for adults and children 12 years and above.

2019+

2022 – Cadila Healthcare Limited rebranded to Zydus Lifesciences Limited. The company’s new brand identity brings together two hearts in purple and teal colors symbolizing its commitment to science and innovation along with care and nurturance.